Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydroxyl Dendrimer,Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ashvattha Presents Positive Phase 2 Data On Migaldendranib at Angiogenesis 2025
Details : D-4517.2 (migaldendranib) is a novel subcutaneously (subQ) administered nanomedicine treatment for retinal diseases and has the potential to be administered at home.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Hydroxyl Dendrimer,Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Tribe Capital
Deal Size : $50.0 million
Deal Type : Series B Financing
Ashvattha Therapeutics Announces $50M Financing and Interim Phase 2 Results
Details : The funding will enable Ashvattha to complete the ongoing mid-stage trial studies of D-4517.2 (dendranib). It is being evaluated for the treatment of wet-AMD.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Tribe Capital
Deal Size : $50.0 million
Deal Type : Series B Financing
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) is a potent, subcutaneously administered anti-angiogenic nanomedicine. It is in phase 2 cliniclal studies for treatment of neovascular age-related macular degeneration (wet AMD) and diabetic m...
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings
Details : Ashvattha will present preclinical data at ARVO on its oral formulation of D-4517.2, a potent anti-angiogenic nanomedicine, in a laser-induced choroidal neovascularization (CNV) mouse model, and compare its efficacy with intravitreal aflibercept.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First stage of study will evaluate safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 (hydroxyl dendrimer) compared to intravitreal (IVT) injection of aflibercept,in both wet AMD and DME patients up to 1...
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
September 07, 2022
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OP-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data showed OP-101 (N-acetyl Cysteine) delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with severe COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : OP-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data demonstrate its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 18-F OP-801
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Details : 18-F OP-801 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : 18-F OP-801
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : D-4517.2
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
Details : D-4517.2 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : D-4517.2
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In animal toxicology studies, D-4517.2 demonstrated no evidence of genotoxicity and showed local reversible changes at the injection site when administered at dosages several times higher than the effective dose range determined for humans.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Hydroxyl Dendrimer
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable